CytoDyn Shows Statistically Significant Fibrosis

CytoDyn Shows Statistically Significant Fibrosis Reversal

CytoDyn Inc. announced positive preclinical results for leronlimab, demonstrating a statistically significant reversal of liver fibrosis in three separate studies conducted with SMC Laboratories. These studies utilized different models of liver fibrosis, including a high-fat diet and a fibrosis-inducing agent, and all showed leronlimab monotherapy significantly outperformed the control group. The company believes this is due to leronlimab’s ability to bind to CCR5 receptors on hepatic stellate cells.

This preclinical success strengthens the potential of leronlimab as a treatment for liver fibrosis, an area with significant unmet medical need. Current treatment options for liver fibrosis are limited, and the progression to cirrhosis can lead to liver failure and the need for transplantation. Leronlimab’s mechanism of action, targeting CCR5 receptors, suggests it could offer a new and potentially effective approach to managing and even reversing this condition. The diverse models used in the studies provide a broader base of evidence for leronlimab’s efficacy. This could accelerate the development of leronlimab for liver fibrosis and potentially expand its application to other fibrotic diseases in organs like the lungs and heart.

The studies evaluated leronlimab in mouse models using both a high-fat diet combined with a single dose of Streptozocin, and a fibrosis-inducing agent. All three studies demonstrated a statistically significant reversal of liver fibrosis (p-values < 0.01) compared to the control group. While CytoDyn is prioritizing its oncology objectives for 2025, it is actively seeking partnerships to advance leronlimab’s clinical development for liver fibrosis and other potential indications. These positive preclinical findings represent a crucial step towards developing a much-needed treatment for liver fibrosis. The potential for partnerships and further clinical trials suggests that leronlimab could eventually offer a new therapeutic avenue for patients with this serious condition. Furthermore, the potential application of leronlimab to other fibrotic diseases may broaden its impact across multiple therapeutic areas. This development positions leronlimab as a promising candidate in an area of high unmet medical need and reinforces the potential of CCR5 antagonism as a therapeutic strategy.

https://www.clinicaltrialvanguard.com/news/cy...-reversal/